# SMP-3124LP in Adults With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06526819/  
OnCo record `nct06526819` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SMP3124LP in advanced solid tumours, run by Sumitomo Pharma America, Inc., now recruiting.

## Summary

SMP-3124LP in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06526819 by Sumitomo Pharma America, Inc., with 120 participants planned, started 2024-08-14 and due to reach its primary completion in 2028-12. Interventions recorded: SMP3124LP.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06526819
- Phase: 1/2
- Setting: An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors
- Sponsor: Sumitomo Pharma America, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06526819: https://clinicaltrials.gov/study/NCT06526819

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06526819.json